Trial Profile
Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2018
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
- Focus Therapeutic Use
- 02 Mar 2018 Status changed to withdrawn prior to enrolment as competing studies did not allow enrolment.
- 28 Feb 2017 New trial record